Fortress Biotech repays final $15M Oaktree debt, terminates $50M secured credit facility

Fortress Biotech, Inc.

On September 30, 2026 repaid $15.0M remaining principal under the Oaktree senior secured credit agreement, plus ~$435,000 accrued interest and a $150,000 prepayment fee.
All liens and security interests in Company property were released and terminated; the Oaktree Agreement automatically terminated per its terms.
Original $50.0M facility with Oaktree Fund Administration, LLC was entered July 25, 2024 and amended December 12, 2025 and February 22, 2026.
Repayment clears all remaining indebtedness under the facility, leaving the company with no obligations to the Oaktree lenders.
8-K signed by CFO David Jin and dated October 1, 2026; no new guidance or financial results provided.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.